China has caught up in a short period of time, not only in the area of GMP compliance but also in the field of process and plant technology when it comes to modern biotechnology processes for the manufacture of innovative products. The evolution from a generic drug manufacturer to a producer of its own pipeline products is unmistakable. This raises the question of whether China will be more of a competitor or a partner in the global development of modern pharmaceuticals in the future.
This question is the focus of the new technical article from gempex:
Ralf Gengenbach, CHEManager, 09-2026: “China’s Biotechnology in Transition.”
Drawing on more than 20 years of experience in GMP-regulated industries in China and the projects of the subsidiary gempex China Ltd. - which now operates from three locations in China - the article examines this development and provides insights into the current situation.
Key topics are:
- High-level quality standards and inspectors
- Technology and support for the design of modern pharmaceuticals
- From contract manufacturer to producer of its own pipeline products
- China as an equal partner in the field of biotechnology
The German language article is available for download at www.gempex.com/GMP-Knowledge.
For any questions regarding GMP in China or the biotechnology market in China, please contact Ralf Gengenbach, Managing Director gempex GmbH, via contact@gempex.com.
This might also interest you:
gempex/locations/gempexChina Ltd.